Overview
Randomized Trial of Ultrashort Psychotherapy vs Sustained-Release Bupropion for Smoking Cessation
Status:
Completed
Completed
Trial end date:
2007-01-01
2007-01-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Background Smokers often reject drugs as smoking cessation aids. Nonpharmacological interventions are notoriously under-evaluated. Methods We conducted a randomized clinical trial in which we compared a medication, i.e., sustained-release bupropion (Zyban®; 413 subjects), at the time of the trial the most efficacious pharmacological smoking cessation aid, with an ultrashort psychotherapeutic intervention, Psychodynamic Model Training® (366 subjects), a manual-based psychodynamically oriented 1 ½ day autosuggestion training. Outcome criterion was 12-month self-reported continuous abstinence confirmed by urine cotinine levels below the level of detection (13 ng/ml) or, in an independent analysis, by exhaled carbon monoxide of 10 ppm or less at all interviews conducted at 3, 6, and 12 months.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Medical University InnsbruckTreatments:
Bupropion
Criteria
Inclusion Criteria:- An age of at least 18 years,
- A cigarette consumption of at least 15 cigarettes per day in the last 3 months, and
- The willingness to contribute EUR 70 to the treatment costs, regardless of the
treatment modality.
Exclusion Criteria:
- Any psychiatric diagnosis except nicotine or caffeine dependence,
- Any current psychopharmacological treatment,
- Known hypersensitivity to bupropion,
- Epilepsy,
- Liver cirrhosis,
- Brain tumor,
- Pregnancy (verified by an immunological test at the intake interview and 3 weeks after
the first day of the first menses occurring within treatment),
- Lactation,
- Any serious or unstable cardiac,
- Renal,
- Hypertensive,
- Pulmonary,
- Endocrine, or neurologic disorder,
- Ulcers,
- Dermatologic disorders,
- Current use of other smoking cessation treatments, and
- Regular use of any noncigarette tobacco product